Israeli scientists say they have developed a new and potentially more reliable method for assessing vaccine safety — using smart sensors instead of relying on patients reporting on how they feel.

A research team from Tel Aviv University attached electronic sensors to the chests of 160 Israelis receiving their second coronavirus shot. The results of their study have been peer-reviewed and published in Communications Medicine, a journal from the Nature portfolio.

The sensors measured physiological reactions from one day before to three days after receiving the vaccine. They monitored heart rate, breathing rate, blood oxygen levels, heartbeat volume, temperature, cardiac output, and blood pressure.

The study gave a far more detailed view of the body’s reaction to the vaccine than any previous research, according to Dr. Dan Yamin of Tel Aviv University’s Epidemic Research Center.

“Normally, vaccine trials rely heavily on what people say about themselves and how they’re feeling, but this study opens up the possibility that we can take a much more objective approach,” Yamin told The Times of Israel.

“We fitted people with sensors that gathered accurate information for days after vaccination, and it’s possible that vaccine trials of the future will take this approach.”

An Israeli woman receiving a coronavirus vaccine (AP Photo/Maya Alleruzzo)

He said the study provided the “proof of concept” that his team was looking for, and added, “This could be a game-changer.”

Yamin stressed that the overall results posed no challenge to the understanding that coronavirus vaccines are safe — saying the important thing is that the trials were detailed enough to flag side effects.

The study picked up physiological signs of notable short-term side effects. In the case of the COVID shots they mostly subside after 48 hours and don’t cause health problems beyond grogginess. But the system is tuned to detect longer-lasting side effects, and will be put to the test on other vaccines in due course, Yamin said.

Dr. Dan Yamin of Tel Aviv University (Moshe Baderashi)

He suggested that if deployed, smart sensors could eventually reduce the number of people needed for trials, because if data is more objective and reliable, smaller sample sizes may suffice.

Yamin’s colleague Dr. Yftach Gepner, who led the research, commented: “The message from our study is clear. In 2022 the time has come to conduct continual, sensitive, objective testing of the safety of new vaccines and therapies. There is no reason to rely on self-reports or wait for the occurrence of rare side effects. Preliminary signs that predict such conditions can be detected with advanced sensors.”

Gepner added: “Today trial participants are invited to the clinic for blood pressure testing, but often their blood pressure rises just because the situation is stressful. Continual monitoring at home solves these problems with simple, convenient, inexpensive, and accurate means. This is the kind of medicine we should strive for.”

We're telling a critical story

Israel is now a far more prominent player on the world stage than its size suggests. As The Times of Israel's Diplomatic Correspondent, I'm well aware that Israel's security, strategy and national interests are always scrutinized and have serious implications.

It takes balance, determination, and knowledge to accurately convey Israel's story, and I come to work every day aiming to do so fully. 

Financial support from readers like you allows me to travel to witness both war (I just returned from reporting in Ukraine) and the signing of historic agreements. And it enables The Times of Israel to remain the place readers across the globe turn to for accurate news about Israel's relationship with the world.

If it's important to you that independent, fact-based coverage of Israel's role in the world exists and thrives, I urge you to support our work. Will you join The Times of Israel Community today?

Thank you,

Lazar Berman, Diplomatic Correspondent

Yes, I'll give

Yes, I'll give

Already a member? Sign in to stop seeing this

You're a dedicated reader

That’s why we started the Times of Israel ten years ago - to provide discerning readers like you with must-read coverage of Israel and the Jewish world.

So now we have a request. Unlike other news outlets, we haven’t put up a paywall. But as the journalism we do is costly, we invite readers for whom The Times of Israel has become important to help support our work by joining The Times of Israel Community.

For as little as $6 a month you can help support our quality journalism while enjoying The Times of Israel AD-FREE, as well as accessing exclusive content available only to Times of Israel Community members.

Thank you,
David Horovitz, Founding Editor of The Times of Israel

Join Our Community

Join Our Community

Already a member? Sign in to stop seeing this

Source link